抗整合素藥市場規模·對象患者族群·競爭情形·市場預測 (～2034年)

本報告詳細介紹了美國、歐盟四國（德國、法國、義大利、西班牙）、英國和日本的抗整合素藥物市場規模、目標病患群體、競爭格局及未來市場趨勢。

本報告深入分析了抗整合素藥物、已核准（如有）和新興療法的治療現狀、每種藥物的市場份額以及抗整合素藥物的目標患者群體。報告也分析了七大市場（美國、歐盟四國、英國和日本）2020年至2034年按藥物和適應症劃分的當前和預測市場規模。本報告也探討了目前未滿足的需求和挑戰、新型治療藥物融入治療體系的情況，以及新興藥物在可及性和接受度方面的區域差異。它還包括對抗整合素藥物定價和報銷的見解，旨在評估市場潛力並確定最佳商業機會。

目標地區

• 美國
• 歐盟四國（德國、法國、義大利、西班牙）、英國
• 日本

研究週期：2020-2034

研究範圍：

• 包含選定的關鍵事件、摘要整理、目標患者群體、流行病學和市場預測、患者治療途徑以及各種生物標誌物檢測率的信息
• 全面描述已上市和新興療法，深入了解抗整合素藥物的目標患者族群
• 詳細回顧抗整合素藥物市場，包括歷史和預測市場規模、按治療類別劃分的市場份額、詳細假設和方法論依據
• SWOT 分析、專家/KOL 意見和治療偏好。了解這些趨勢有助於制定商業策略，並有助於塑造和推動市場七大經濟體中抗整合素藥物市場。
• 治療藥物和適應症劃分的抑制劑市場規模

抗整合素藥物報告的主要優點

• 11年市場預測
• 700萬市場覆蓋率
• 已上市及新興療法的競爭格局
• 抗整合素藥物的可覆蓋患者總數
• 藥物滲透狀況與關鍵市場預測假設
• 已獲批准和計劃中的療法概況
• 醫師觀點/KOL意見
• 生物標記檢測與病患治療途徑
• 定性分析（SWOT和分析師觀點）
• 依治療藥物和適應症劃分的市場規模
• 現有與未來的市場機遇
• 未滿足的需求

頻繁常見問題

• 2020 年的整體市場規模、各治療藥物的市場規模以及市佔率分佈如何？ 2034 年的情況又會如何？抗整合素藥物市場的成長驅動力有哪些？
• 到 2034 年，哪一種 KRAS 抑制劑的貢獻最大？
• 抗整合素藥物的市場進入和報銷情況如何？
• 各地區的定價趨勢如何？
• 市場驅動因素、障礙和未來機會如何影響市場動態和相關趨勢的分析？
• 為了克服現有療法的局限性，正在開發哪些最新的新型治療藥物、標靶、作用機制和技術？
• 在現實場景中，基於病患治療偏好的可接受性如何？

目錄

第1章 重要的洞察

第2章 報告簡介

第3章 抗整合素藥:摘要整理

第4章 主要事件

第5章 抗整合素藥:市場概要

• 2023年的市場佔有率 (%) 分佈
• 2034年的市場佔有率 (%) 分佈

第6章 背景·概要

第7章 對象族群

第8章 抗整合素藥:已上市藥

• 主要企業
• 產品說明
• 法規的里程碑
• 其他的開發活動
• 進行中的臨床開發
• 安全性和有效性

第9章 抗整合素藥:新興藥

• 主要企業
• 產品說明
• 其他的開發活動
• 臨床開發
• 安全性和有效性

第10章 分析抗整合素藥:主要7個國家

• 主要調查結果
• 市場預測
• 主要的前提條件
• 主要7個國家的整體市場規模
  • 市場規模:各治療藥物
  • 市場規模:各適應症
• 美國
  • 市場規模
  • 市場規模:各治療藥物
• EU4·英國
  • 市場規模
  • 市場規模:各治療藥物
• 日本
  • 市場規模
  • 市場規模:各治療藥物

第11章 未滿足需求

第12章 SWOT分析

第13章 KOL的見解

第14章 市場進入與償付

• 美國
• EU4·英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
• 日本

第15章 附錄

第16章 DelveInsight的功能

第17章 免責聲明

第18章 關於DelveInsight

DelveInsight's "Anti-integrin Agents Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report delivers an in-depth understanding of Anti-integrin Agents, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The Anti-integrin Agents market report provides insights around existing treatment practices in patients with Anti-integrin Agents, approved (if any) and emerging Anti-integrin Agents, market share of individual therapies, patient pool eligible for treatment with Anti-integrin Agents, along with current and forecasted 7MM Anti-integrin Agents market size from 2020-2034 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new Anti-integrin Agents in different geographies, along with insights on Anti-integrin Agents pricing reimbursements to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain), and the UK
• Japan

Study Period: 2020-2034

Anti-integrin Agents Overview

This segment will provide detailed information beginning with the inhibitor journey from discovery of the mutation or protein expression to its entry into clinical development followed by its upcoming commercial potential. This segment will dive into the different indications for which the inhibitor is being developed for, which would further give insights on the potential addressable patient population. Moreover, this segment will also give a brief overview around the existing treatment paradigm of the target indications.

Anti-integrin Agents in Clinical Practice

This section will give in depth information about the existing local and systemic options in the current treatment paradigm of all the potential indications, in which most of the pharmaceutical companies are actively evaluating their inhibitors. Potential of the emerging Anti-integrin Agents in changing the current clinical practice guidelines is crucial to analyze especially when it comes to real world scenario.

It will also include the relevance and importance of incorporation of biomarker testing at varying stages of the disease. It is also important to understand that implementing such tests in routine clinical practice is not uniform in different countries due to issues such as cost, accessibility, reimbursement and non-recommendation in guidelines.

Anti-integrin Agents Drug Chapters

The drug chapter segment of the Anti-integrin Agents report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the Anti-integrin Agents clinical trial details, pharmacological action, agreements and collaborations related to Anti-integrin Agents, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

Anti-integrin Agents Marketed Drugs

The Anti-integrin Agents marketed drug section will provide detailed drug profiles of already approved therapies. Information around clinical development activities, launch timing, regulatory milestones along with safety and efficacy data of the therapy will be included.

Anti-integrin Agents Emerging Drugs

Apart from a comprehensive Anti-integrin Agents competitive landscape in tabular form, the emerging KRAS Inhibitor chapters provides the product details and other development activities of the emerging Anti-integrin Agents under the late and mid-stage of clinical development for various indications.

Drug Class Insights

The Drug Class Insights section will provide comprehensive information on Anti-integrin Agents as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of Anti-integrin Agents, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

Anti-integrin Agents Market Outlook

This section will include details on changing Anti-integrin Agents market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial's inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

Anti-integrin Agents Drugs Uptake

This section focuses on the uptake rate of potential Anti-integrin Agents already launched and expected to be launched in the market during 2020-2034, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Anti-integrin Agents Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Anti-integrin Agents Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Anti-integrin Agents.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher's, and other Industry Experts' opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on Anti-integrin Agents' incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Report:

• The report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
• Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on Anti-integrin Agents addressable patient pool
• A detailed review of the Anti-integrin Agents market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM Anti-integrin Agents market.
• Market Size of Inhibitors by therapies and indication will be provided

Anti-integrin Agents Report Key Strengths

• 11 Years Anti-integrin Agents Market Forecast
• The 7MM Coverage
• Anti-integrin Agents Competitive Landscape of current and emerging therapies
• Anti-integrin Agents Total Addressable patient population
• Drugs Uptake and Key Market Forecast Assumptions
• Approved and Emerging therapy Profiles
• Physician's perspectives/KOL opinions
• Biomarker testing and Patient journey
• Qualitative Analysis (SWOT and Analyst Views)
• Anti-integrin Agents Market Size by therapy and indication
• Existing and Future Market Opportunity
• Unmet Needs

FAQs:

• What was the Anti-integrin Agents total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for Anti-integrin Agents market growth?
• Which KRAS Inhibitor is going to be the largest contributor by 2034?
• What is the market access and reimbursement scenario of Anti-integrin Agents?
• What are the pricing variations among different geographies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Anti-integrin Agents Market.
• Understand the existing Anti-integrin Agents market opportunities and future trends in varying geographies
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility and acceptability of emerging treatment options along with unmet need of current therapies
• Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies' development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Anti-integrin Agents

4. Key Events

5. Anti-integrin Agents Market Overview At A Glance

• 5.1. Market Share (%) Distribution of Anti-integrin Agents By Therapy in 2023
• 5.2. Market Share (%) Distribution of Anti-integrin Agents By Therapy in 2034

6. Background And Overview

7. Target Population

8. Anti-integrin Agents Marketed Drugs

• 8.1. Key Competitors
• 8.2. Company 1: Product 1
  • 8.2.1. Product Description
  • 8.2.2. Regulatory Milestones
  • 8.2.3. Other Developmental Activities
  • 8.2.4. Ongoing Clinical Development
  • 8.2.5. Safety and Efficacy
• 8.3. Company 2: Product 2
  • 8.3.1. Product Description
  • 8.3.2. Regulatory Milestones
  • 8.3.3. Other Developmental Activities
  • 8.3.4. Ongoing Clinical Development
  • 8.3.5. Safety and Efficacy

9. Anti-integrin Agents Emerging Drugs

• 9.1. Key Competitors
• 9.2. Company 1: Product 1
  • 9.2.1. Product Description
  • 9.2.2. Other Development Activities
  • 9.2.3. Clinical Development
    • 9.2.3.1. Clinical Trials Information
  • 9.2.4. Safety and Efficacy
• 9.3. Company 2: Product 2
  • 9.3.1. Product Description
  • 9.3.2. Other Development Activities
  • 9.3.3. Clinical Development
    • 9.3.3.1. Clinical Trials Information
  • 9.3.4. Safety and Efficacy

10. Anti-integrin Agents: The 7MM Analysis

• 10.1. Key Findings
• 10.2. Market Outlook
• 10.3. Key Market Forecast Assumptions
• 10.4. Total Market Size of Anti-integrin Agents in the 7MM
  • 10.4.1. Market Size of Anti-integrin Agents By Therapies In the 7MM
  • 10.4.2. Market Size of Anti-integrin Agents By Indication In the 7MM
• 10.6. United States Market
  • 10.6.1. Total Market Size of Anti-integrin Agents in the United States
  • 10.6.2. Market Size of Anti-integrin Agents By Therapies in the United States
• 10.7. EU4 and the UK Market
  • 10.7.1. Total Market Size of Anti-integrin Agents in EU4 and the UK
  • 10.7.2. Market Size of Anti-integrin Agents By Therapies in EU4 and the UK
• 10.8. Japan Market
  • 10.8.1. Total Market Size of Anti-integrin Agents in Japan
  • 10.8.2. Market Size of Anti-integrin Agents By Therapies in Japan

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Market Access and Reimbursement

• 14.1. United States
  • 14.1.1. Centre for Medicare & Medicaid Services (CMS)
• 14.2. EU4 and the UK
  • 14.2.1. Germany
  • 14.2.2. France
  • 14.2.3. Italy
  • 14.2.4. Spain
  • 14.2.5. United Kingdom
• 14.3. Japan
  • 14.3.1. MHLW

15. Appendix

• 15.1. Bibliography
• 15.2. Report Methodology

16. Delveinsight Capabilities

17. Disclaimer

18. About DelveInsight

List of Tables

• Table 1: Target Population in the 7MM (2020-2034)
• Table 2: Marketed Drug Key cross
• Table 3: Product 1, Clinical Trial Description, 2024
• Table 4: Product 2, Clinical Trial Description, 2024
• Table 5: Emerging Drug Key cross
• Table 6: Product 1, Clinical Trial Description, 2024
• Table 7: Product 2, Clinical Trial Description, 2024
• Table 8: Total Anti-integrin Agents Market Size in the 7MM (2020-2034)
• Table 9: Anti-integrin Agents Market Size by Therapies in the 7MM (2020-2034)
• Table 10: Anti-integrin Agents Market Size by Indication in the 7MM (2020-2034)
• Table 11: Total Anti-integrin Agents Market Size in the United States (2020-2034)
• Table 12: Anti-integrin Agents Market Size by Therapies in the United States (2020-2034)
• Table 13: Total Anti-integrin Agents Market Size in EU4 and the UK (2020-2034)
• Table 14: Anti-integrin Agents Market Size by Therapies in EU4 and the UK (2020-2034)
• Table 15: Total Anti-integrin Agents Market Size in Japan (2020-2034)
• Table 16: Anti-integrin Agents Market Size by Therapies in Japan (2020-2034)

List of Figures

• Figure 1: Target Population in the 7MM (2020-2034)
• Figure 2: Total Anti-integrin Agents Market Size in the 7MM (2020-2034)
• Figure 3: Anti-integrin Agents Market Size by Therapies in the 7MM (2020-2034)
• Figure 4: Anti-integrin Agents Market Size by Indication in the 7MM (2020-2034)
• Figure 5: Total Anti-integrin Agents Market Size in the United States (2020-2034)
• Figure 6: Anti-integrin Agents Market Size by Therapies in the United States (2020-2034)
• Figure 7: Total Anti-integrin Agents Market Size in EU4 and the UK (2020-2034)
• Figure 8: Anti-integrin Agents Market Size by Therapies in EU4 and the UK (2020-2034)
• Figure 9: Total Anti-integrin Agents Market Size in Japan (2020-2034)
• Figure 10: Anti-integrin Agents Market Size by Therapies in Japan (2020-2034)